Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

By B. J. Gersh. 2011

2,712 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/40fa613dcf7d4bac9d7b1ea08fe96a9fb9308b3b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. I. Graham
2. Børge G. Nordestgaard
3. A. Goldfine
4. W. Hiatt
5. Cecilia C. Low Wang
6. Connie N. Hess

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. Børge G. Nordestgaard
3. Jan Boren
4. A. Tybjærg-Hansen
5. Marja-Riitta Taskinen
6. M. Chapman
7. Alberico L. Catapano
8. B. Lacey

In Surgery

1. I. Graham
2. Jan Boren
3. A. Tybjærg-Hansen
4. Børge G. Nordestgaard
5. M. Chapman
6. Marja-Riitta Taskinen
7. Alberico L. Catapano
8. J. Armitage

Citations in the corpus

• Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention (2014, neutral): “particularly in randomized trials (92).”
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “8 mmol/L ( 70 mg/dL) is associated with the lowest risk of recurrent CVD events in secondary prevention populations.(459) Therefore, for high-risk subjects, the target LDL cholesterol level should be ,1.”
• Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (2016, positive): “Then clinical interest focused (rightfully so) on LDL cholesterol, caused by several factors of which the most important were demonstration of mutations in the LDL receptor as the cause of familial hypercholesterolemia with high LDL levels and premature ASCVD,(19) leading to the Nobel Prize award to”